Clinical trials: Biliary Cancers
Biliary Tract Neoplasms, Liver Cancer
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response.
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT02821754
- Testing
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Colon and Rectal Cancer
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.
- Trial name
- GAP Cemi (NCT07433673)
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Jaundice, Obstructive, Klatskin Tumor
Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice
The purpose of this study is to evaluate the safety and effectiveness of different methods of preoperative biliary drainage in patients with extrahepatic bile duct neoplasms with obstructive jaundice (hilar cholangiocarcinoma…
- Trial name
- NCT03527875
- Testing
- PTBD group, ENBD group, EBS group
- Volunteers
- 564 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Biliary Tract Adenocarcinoma, Gemcitabine
A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
The role of systemic chemotherapy in advanced biliary tract cancer (BTC) is known to be very limited although various single-agent or combination therapies had been tested.
- Conditions
- Advanced Biliary Tract Adenocarcinoma, Gemcitabine, Oxaliplatin, Combination Chemotherapy
- Trial name
- NCT00504192
- Testing
- Gemcitabine and Oxaliplatin
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Soonchunhyang University Hospital
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Advanced Biliary Tract Cancer
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.
- Trial name
- NCT06978114
- Testing
- BL-B01D1, Pembrolizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Pancreatic Neoplasms, Cholestasis
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
The purpose of this study is to determine the safety and pharmacokinetic profile of nab®-paclitaxel (ABI-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile…
- Trial name
- NCT02267707
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 6 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- Celgene
Biliary Tract Neoplasms
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
To evaluate the following items in patients with locally advanced and metastatic biliary tract cancer receiving SLOG or GC treatment, Primary objective: 6-month progression-free survival rate Secondary objectives: Objective…
- Trial name
- NCT03406299
- Testing
- Tegafur, Leucovorin, Oxaliplatin
- Where
- Taiwan
- Volunteers
- 92 people
- Sponsor
- National Health Research Institutes, Taiwan
Bile Duct Cancer
Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy
The purpose of this study is to determine whether preoperative immunonutrition is effective on infectious complication and Th1/Th2 differentiation in patients with major hepatectomy.
- Trial name
- NCT01256047
- Testing
- Oral IMPACT
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Chiba University
Hepatobiliary Neoplasm, Liver Neoplasm
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
The investigators design a phase II clinical study to explore the efficacy and safety of axitinib plus toripalimab as a second-line treatment in patients with hepatobiliary malignant tumors and to analyze potential biomarkers of…
- Conditions
- Hepatobiliary Neoplasm, Liver Neoplasm, Biliary Tract Neoplasms
- Trial name
- NCT04010071
- Testing
- axitinib plus toripalimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Endometrial Cancer, Gastric Cancer
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid…
- Conditions
- Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
- Trial name
- NCT05489211
- Testing
- Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil
- Where
- 96 sites in United States, Canada and 12 more
- Volunteers
- 454 people
- Sponsor
- AstraZeneca
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Hepatectomy, NGS
Diagnostic Value of Next-Generation Sequencing Analysis in Biliary Tract Tumours
The aim of this study is to identify a dysplasia- and CCA-specific NGS panel to increase the diagnostic sensitivity of histological and/or cytological examination of biliary tract stenosis.
- Conditions
- Hepatectomy, NGS, Stenosis of Bile Duct
- Trial name
- NCT06729944
- Testing
- NGS
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Biliary Tract Cancer, Melanoma
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase IIa study of HX009+ IN10018 in combination with or without standard chemotherapy in patients with advanced solid tumours including biliary tract malignancies and malignant melanoma
- Trial name
- NCT06708663
- Testing
- HX009+IN10018
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Biliary Tract Cancer
RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2
This study was a prospective, single-arm phase II clinical trial to observe and evaluate the efficacy and safety of RC48-ADC combined envafolimab in the first-line treatment of locally advanced or metastatic biliary tract cancer…
- Trial name
- NCT05417230
- Testing
- RC48-ADC, Envafolimab
- Volunteers
- 29 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Acute Pancreatitis Due to Gallstones
Inmediate Feeding Tolerance in Acute Pancreatitis
Objective: Determine tolerance of immediate oral intake (8 hours posterior to the beginning of treatment) against traditional management (early feeding at 48hr) in patients with mild acute pancreatitis of biliary origin.
- Trial name
- NCT03354065
- Testing
- TIME OF FEEDING
- Volunteers
- 59 people
- Sponsor
- Hospital Central "Dr. Ignacio Morones Prieto"
Pancreatic Cancer, Common Bile Duct Diseases
A Multicenter Prospective Randomized Controlled Study of RPD Versus LPD
laparoscopic pancreaticoduodenectomy(LPD) and Robot Pancreaticoduodenectomy (RPD), as two minimally invasive methods of pancreaticoduodenectomy(PD), have obvious advantages over traditional open pancreaticoduodenectomy(OPD) in…
- Conditions
- Pancreatic Cancer, Common Bile Duct Diseases, Periampullary Carcinoma
- Trial name
- NCT05755607
- Testing
- laparoscopic pancreaticoduodenectomy, Robot Pancreaticoduodenectomy
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of University of South China
Biliary Tract Cancer
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer.
- Trial name
- NCT04935853
- Where
- 32 sites in France
- Volunteers
- 1,350 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.